Asset Details
Do you wish to reserve the book?
Principles of diagnosis and management of neuroendocrine tumours
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Principles of diagnosis and management of neuroendocrine tumours
Do you wish to request the book?
Principles of diagnosis and management of neuroendocrine tumours
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Principles of diagnosis and management of neuroendocrine tumours
2017
Overview
The second modality is functional imaging, which takes advantage of the overexpression of somatostatin receptors commonly seen in NETs. Radiolabelled somatostatin analogues are administered intravenously, concentrate in NETs, and the emitted radiation is detected to localize tumours. 111Indium (In)labelled pentetreotide is the most commonly used radiotracer in Canada. A recent meta-analysis of molecular imaging methods for NETs reported that 111In-labelled pentetreotide somatostatin receptor scintigraphic imaging had a sensitivity of 46%-100% for abdominal NETs, 46%-83% for pancreatic NETs and 71% for bronchial NETs.45 Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor that is thought to act by inhibiting cell proliferation, angiogenesis and cell metabolism. Everolimus has proven progression-free survival benefit in well-conducted phase 3 RCTs in gastrointestinal and lung NETs,62-64 and pancreatic NETs.65,66 In the RADIANT-4 phase III RCT involving 302 patients with advanced progressive nonfunctional lung or gastrointestinal NETs, everolimus was associated with a 52% reduction in the risk of progression or death (HR 0.48, 95% CI 0.35-0.67) compared with placebo. Similarly, in the RADIANT-3 phase 3 RCT involving 410 patients with advanced low- or intermediate-grade pancreatic NETs, everolimus was associated with a 65% reduction in the risk of progression or death (HR 0.35, 95% CI 0.27-0.45) compared with placebo. We searched MEDLINE, Embase, Google Scholar and the Cochrane Database of Systemic Reviews for articles relating to the diagnosis, classification and management of neuroendocrine tumours. Search terms included \"neuroendocrine tumors,\" \"neuroendocrine neoplasms,\" \"carcinoid tumors,\" \"islet cell tumors\" and \"bronchopulmonary neuroendocrine tumors.\" We then searched for abstracts from major international oncology conferences to identify any recently completed studies. The reference lists of all relevant articles were reviewed for studies not captured in the original search.
Publisher
Elsevier Inc,CMA Impact Inc,Joule Inc,CMA Impact, Inc
Subject
/ Diarrhea
/ Hormones
/ Humans
/ Intestinal Neoplasms - complications
/ Intestinal Neoplasms - diagnosis
/ Intestinal Neoplasms - pathology
/ Intestinal Neoplasms - therapy
/ Ischemia
/ Lung Neoplasms - complications
/ Malignant Carcinoid Syndrome - etiology
/ Neuroendocrine Tumors - complications
/ Neuroendocrine Tumors - diagnosis
/ Neuroendocrine Tumors - pathology
/ Neuroendocrine Tumors - therapy
/ Pancreatic Neoplasms - complications
/ Pancreatic Neoplasms - diagnosis
/ Pancreatic Neoplasms - pathology
/ Pancreatic Neoplasms - therapy
/ Peptides
/ Positron Emission Tomography Computed Tomography
/ Review
/ Surgical Procedures, Operative
/ Tumors
